The basis for aldose reductase (AR) inhibition in diabetes is the high AR pathway activity in the peripheral nerve and other tissues that are susceptible to complications related to diabetes, and its activation by hyperglycemia [5]. This evidence concerns the gene AR and diabetes mellitus.